Abstract
To date, the manufacturer of sorafenib has reported that the hyponatremia and thrombocytopenia associated with its use are generally moderate and tolerable and have resulted in no mortalities. In this article we describe a Japanese patient with severe hyponatremia and thrombocytopenia that were likely related to sorafenib treatment for metastatic renal carcinoma. Oncologists should be aware of hyponatremia and thrombocytopenia as an adverse effect related to this agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
